NHS to roll-out tocilizumab treatment for COVID-19
In the RECOVERY trial, tocilizumab treatment significantly reduced deaths caused by COVID-19
Read More
Tag: tocilizumab
Roche begins trial of Actemra/RoActemra plus remdesivir
The trial will test the potential of combining an antiviral with an immune modulator
Read More
NHS England clears specialised treatments for NHS use
NHS England has approved routine funding for a stream of new specialised treatments, including stroke-reducing heart implants and a life changing surgical procedure for children with cerebral palsy.
Read More
Final NHS nod for Roche’s RoActemra
Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.
Read More
NICE u-turn on treatment for giant cell arteritis
Roche/Chugai’s RoActemra has now won the backing of the National Institute of Health and Care Excellence for the treatment of eligible patients with giant cell arteritis (GCA).
Read More
NHS use of Roche’s Roactemra turned down for giant cell arteritis
It is looking unlikely that patients with giant cell arteritis will get NHS access to Roche’s Roactemra, after the drug was turned down by cost regulators in draft guidelines.
Read More
US approves first drug for giant cell arteritis
Roche’s Actemra has become the first drug approved by US regulators specifically to treat giant cell arteritis, a form of vasculitis that results in inflammation of blood vessels.
Read More
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
